- Home
- NDLS vs DYAI Comparison
NDLS vs DYAI Comparison
Compare NDLS & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- DYAI
- Stock Information
- Founded
- NDLS 1995
- DYAI 1979
- Country
- NDLS United States
- DYAI United States
- Employees
- NDLS N/A
- DYAI N/A
- Industry
- NDLS Restaurants
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDLS Consumer Discretionary
- DYAI Health Care
- Exchange
- NDLS Nasdaq
- DYAI Nasdaq
- Market Cap
- NDLS 32.9M
- DYAI 29.6M
- IPO Year
- NDLS 2013
- DYAI 2004
- Fundamental
- Price
- NDLS $0.80
- DYAI $0.93
- Analyst Decision
- NDLS Strong Buy
- DYAI Strong Buy
- Analyst Count
- NDLS 2
- DYAI 1
- Target Price
- NDLS $3.00
- DYAI $6.00
- AVG Volume (30 Days)
- NDLS 212.2K
- DYAI 60.7K
- Earning Date
- NDLS 08-06-2025
- DYAI 08-12-2025
- Dividend Yield
- NDLS N/A
- DYAI N/A
- EPS Growth
- NDLS N/A
- DYAI N/A
- EPS
- NDLS N/A
- DYAI N/A
- Revenue
- NDLS $495,670,000.00
- DYAI $3,554,344.00
- Revenue This Year
- NDLS $5.37
- DYAI $22.56
- Revenue Next Year
- NDLS $0.68
- DYAI $30.95
- P/E Ratio
- NDLS N/A
- DYAI N/A
- Revenue Growth
- NDLS N/A
- DYAI 57.59
- 52 Week Low
- NDLS $0.55
- DYAI $0.91
- 52 Week High
- NDLS $1.83
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- NDLS 52.86
- DYAI 41.84
- Support Level
- NDLS $0.66
- DYAI $0.91
- Resistance Level
- NDLS $0.82
- DYAI $1.06
- Average True Range (ATR)
- NDLS 0.07
- DYAI 0.06
- MACD
- NDLS 0.01
- DYAI 0.00
- Stochastic Oscillator
- NDLS 87.67
- DYAI 15.33
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.